As of Nov 19, 2026, 1 of 1 active firms rate PROK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PROK EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect ProKidney Corp. to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-0.65, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
$200.0K
Range $200.0K – $200.0K · 1 analysts · -12% YoY
Revenue is expected to reach $200.0K (range $200.0K – $200.0K), -11.5% year-over-year. Full-year consensus is $723.8K, rising to $629.8K next year.
Top analysts covering ProKidney Corp.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PROK.
#1
Jason Gerberry
B of A Securities · Rank #160
Sell
$1.00-4.8% to target
Overall win rate
47%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #171
Neutral
No targeton PROK
Overall win rate
48%
+ Follow
#3
Vamil Divan
Guggenheim · Rank #211
Buy
$7.00+566.7% to target
Overall win rate
48%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$12.00+1042.9% to target
Overall win rate
34%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$10.00+852.4% to target
Overall win rate
38%
+ Follow
PROK stock forecast FAQ
What is PROK's average 12-month price target?+
The 1 active firms with a live target average $12.00 for ProKidney Corp. over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is PROK stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover PROK?+
1 active firms have a recognized rating on ProKidney Corp. as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PROK?+
Among analysts who currently cover PROK, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #160). Their current call is Sell with a $1.00 target.
What is ProKidney Corp.'s projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-0.65, rising to $-0.63 the following year.
How much revenue is ProKidney Corp. expected to report next quarter?+
Consensus revenue is $200.0K (range $200.0K – $200.0K). Full-year revenue is projected at $723.8K, growing to $629.8K next year.
Have analysts been upgrading or downgrading PROK lately?+
As of Nov 19, 2026, 1 of 1 active firms rate PROK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PROK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.